Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat lung cancer: trial tests adding an immunotherapy drug

NCT ID NCT05781308

Ongoing Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

Summary

This study is for people with advanced non-small cell lung cancer that has continued to grow despite receiving both chemotherapy and immunotherapy. Researchers want to see if adding a drug called atezolizumab to a standard two-drug combination (paclitaxel and bevacizumab) can help control the cancer for longer. About 156 participants will be randomly assigned to receive either the standard two-drug combo or the new three-drug combo to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • APHM Hôpital Nord

    Marseille, France

  • CH Annecy Genevois

    Pringy, France

  • CH Avignon

    Avignon, France

  • CH Cholet

    Cholet, France

  • CH Côte Basque

    Bayonne, France

  • CH Le Mans

    Le Mans, France

  • CH Pasteur

    Colmar, France

  • CH Pau

    Pau, France

  • CH Versailles

    Le Chesnay, France

  • CH Villefranche Nord Ouest

    Villefranche-sur-Saône, 69655, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHR Orléans

    Orléans, France

  • CHU Amiens

    Amiens, France

  • CHU Besançon - Hôpital J. MINJOZ

    Besançon, 25030, France

  • CHU Bordeaux Haut-Lévèque

    Pessac, France

  • CHU Côte de Nacre

    Caen, 14000, France

  • CHU Dijon

    Dijon, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, France

  • CHU Lille

    Lille, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rouen

    Rouen, 76031, France

  • CHU Saint Etienne

    Saint-Etienne, France

  • CHU Toulouse

    Toulouse, 31059, France

  • CHU Tours

    Tours, France

  • CHU d'Angers

    Angers, 49033, France

  • Centre Georges-François Leclerc

    Dijon, 21079, France

  • Centre Hospitalier Intercommunal Créteil CHIC

    Créteil, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Chu Grenoble

    Grenoble, 38043, France

  • Clinique Teissier

    Valenciennes, France

  • GHR Mulhouse et Sud Alsace GHRMSA

    Mulhouse, 68070, France

  • Groupe Hospitalier Paris Saint Joseph GHPSJ

    Paris, France

  • HIA Sainte-Anne

    Toulon, 83800, France

  • Hospices Civils de Lyon - URCOT

    Pierre-Bénite, France

  • Hôpital APHP Ambroise Paré

    Boulogne, 92104, France

  • Hôpital BICHAT

    Paris, 75877, France

  • Hôpital Européen

    Marseille, France

  • Hôpital TENON

    Paris, 75970, France

  • Hôpitaux Privés de Metz Robert Schuman

    Metz, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut de Cancerologie de l'Ouest ICO

    Saint-Herblain, France

  • Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, France

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER